Bioventus (BVS) Set to Announce Quarterly Earnings on Tuesday

Bioventus (NYSE:BVS) will be announcing its earnings results before the market opens on Tuesday, November 5th. Analysts expect the company to announce earnings of $0.06 per share for the quarter. Bioventus has set its FY 2024 guidance at 0.360-0.420 EPS.

Bioventus (NYSE:BVS) last posted its earnings results on Tuesday, August 6th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.12. Bioventus had a negative net margin of 7.82% and a positive return on equity of 14.39%. The business had revenue of $151.22 million for the quarter, compared to analyst estimates of $137.70 million. During the same period in the prior year, the company posted $0.14 EPS. On average, analysts expect Bioventus to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Bioventus Price Performance

Shares of Bioventus stock traded up $0.35 on Wednesday, hitting $13.66. The company’s stock had a trading volume of 98,684 shares, compared to its average volume of 387,385. The company has a market capitalization of $1.11 billion, a price-to-earnings ratio of -20.70 and a beta of 0.90. Bioventus has a 1 year low of $3.36 and a 1 year high of $13.72. The company has a debt-to-equity ratio of 1.82, a quick ratio of 0.96 and a current ratio of 1.33. The firm has a fifty day moving average price of $11.35 and a 200-day moving average price of $8.01.

Insider Activity at Bioventus

In other news, Director John A. Bartholdson bought 80,000 shares of Bioventus stock in a transaction on Friday, August 16th. The stock was acquired at an average price of $8.55 per share, with a total value of $684,000.00. Following the completion of the acquisition, the director now directly owns 6,913,857 shares of the company’s stock, valued at $59,113,477.35. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Bioventus news, Director John A. Bartholdson purchased 25,500 shares of the stock in a transaction that occurred on Monday, August 19th. The shares were purchased at an average cost of $8.55 per share, for a total transaction of $218,025.00. Following the completion of the transaction, the director now owns 6,939,357 shares of the company’s stock, valued at $59,331,502.35. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director John A. Bartholdson acquired 80,000 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The shares were acquired at an average cost of $8.55 per share, with a total value of $684,000.00. Following the purchase, the director now owns 6,913,857 shares in the company, valued at $59,113,477.35. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. 32.90% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have recently commented on BVS. Craig Hallum boosted their price objective on Bioventus from $12.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, September 27th. Canaccord Genuity Group boosted their price target on shares of Bioventus from $8.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, August 13th.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.